Aethlon Medical (NASDAQ:AEMD – Get Free Report) announced its earnings results on Wednesday. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.46) by $2.86, FiscalAI reports.
Aethlon Medical Stock Performance
Shares of AEMD traded up $0.08 during mid-day trading on Wednesday, reaching $2.02. The stock had a trading volume of 602,662 shares, compared to its average volume of 343,914. The firm has a market cap of $3.17 million, a price-to-earnings ratio of -0.14 and a beta of 1.49. Aethlon Medical has a 12 month low of $1.36 and a 12 month high of $27.40. The business has a fifty day moving average of $2.23 and a 200 day moving average of $2.51.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aethlon Medical in a research report on Monday, April 20th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Aethlon Medical has a consensus rating of “Reduce”.
Hedge Funds Weigh In On Aethlon Medical
An institutional investor recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC purchased a new position in Aethlon Medical, Inc. (NASDAQ:AEMD – Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 36.57% of Aethlon Medical at the end of the most recent reporting period. 1.99% of the stock is currently owned by hedge funds and other institutional investors.
Aethlon Medical Company Profile
Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.
The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.
Read More
- Five stocks we like better than Aethlon Medical
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
